Care
The European Institute for Innovation and Technology (EIT) Health has announced the acquisition of one of its supported startups PhagoMed GmbH, by BioNTech SE, in a bid to find new and alternative solutions to antibiotics that are losing effectiveness.
It will focus on creating digital solutions for ophthalmic, neurological and psychiatric disorders.
Only 1.3% of images included in the public data set included patient ethnicity.
Ellume began recalling the tests last month for giving false positive results.
The clinical trial results will be used to expand Viome’s mRNA platform, which in May received FDA breakthrough device designation for identifying early signs of oral and throat cancers.
The industrial giant plans to retain a stake of almost 20% in GE Healthcare.
Cue received emergency use authorization for its at-home COVID-19 test in March and went public in September.
The company said the latest round brings its total raise to $47 million.
The tool uses information about pain level, condition and current medication regimen to find an effective dose of opioids.
The scheme is being run in partnership with government technology firm PUBLIC.